Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Harvard Business School
Moodys
Colorcon
Dow

Last Updated: December 14, 2019

DrugPatentWatch Small Molecules Dashboard

Do you need a custom analysis, patent litigation support, or due diligence assistance? Contact Us

Your Other Dashboards:

Biologics Drug Price Drug Sales Litigation Drugs in Development Bulk Data Book: Make Better Decisions

Upgrade for More Features

Upgrade to a full subscription to unlock our entire dataset and to enjoy subscriber-only features.

Whether you need access for yourself or for your whole team, DrugPatentWatch offers subscription plans tailored to your needs. Attractive pricing is available for small groups or for enterprise-wide access.

For more information see the Plans and Pricing and Discount Schedule. Please contact us with any questions.

➤ See Plans and Pricing
Contact Sales

Drug Name

Search by drug name:

DrugPatentWatch Email Alerts

Popular Searches 

US Regulatory and Patent Information 

Single-Source Off-Patent Drugs

Search for Off-Patent Drugs by Number of Sources:

1 Source  2 Sources  3 Sources  4 Sources  1-4 Sources  
Discontinued Drugs
Company Name

Search by company name:

Search
New Drug Application (NDA) Number

Search by NDA number:

Search
Drug Patent Expiration

2019   2020   2021   2022   2023   2024   2025   2026   2027   2028   2029   2030   2031   2032   2033   2034   2035   2036   2037   2038  

Search by patent number:

Search
Regulatory Exclusivity

Search for exclusivity expiring in:

Search

Search by exclusivity type:

Search
Search Text in Patent Claims

Search for a keyword (e.g. surfactant) or a phrase (e.g. substantially pure) in patent claims:

Search

Approval Date

Search for drugs approved in:

Search

Recent Patent Updates

These are patents which have been reported by the FDA since the last major update; they are not yet in the main database.

Recent Additions

All Recent Patent Additions >>

Recent Delistings

All Recently Delisted Patents >>

Patent Challenge and Generic Entry 

Recent Paragraph IV (Patent) Challenges
TradenameSubmission date
TASIGNAOctober 17, 2019
LONSURFSeptember 23, 2019
AGGRASTATAugust 29, 2019

All Paragraph IV Challenges >>

Tentative Approvals (First Generic Entrants)

The "tentative" approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Search by applicant name:

Search

Search by generic drug name:

Search

All Tentative Approvals >>

Authorized Generic Drugs
Tradename Ingredient Marketing Start
CARDIZEM LA diltiazem hydrochloride Nov 25, 2019
NILANDRON nilutamide Nov 22, 2019
CARDIZEM diltiazem hydrochloride Nov 22, 2019

All Authorized Generics >>

International Patent Information 

International Patents

Patents by country:

Search
Supplementary Protection Certificates

Supplementary Protection Certificiates by country:

Search

Drug Class and Dosage 

Medical Subject Heading (MeSH) Category

Search by MeSH Category:
Search

Dosage

Search by dosage:
Search

Raw API and Finished Product Suppliers 

Bulk API Vendors

Search by branded drug / ingredient name:

Search
Finished Product Suppliers

Search by tradename:

Search

Search by ingredient:

Search

Clinical Trials and Trend Graphs 

Clinical Trials

Search by branded drug / ingredient name:

Search

Upgrade for More Features

Upgrade to a full subscription to unlock our entire dataset and to enjoy subscriber-only features.

Whether you need access for yourself or for your whole team, DrugPatentWatch offers subscription plans tailored to your needs. Attractive pricing is available for small groups or for enterprise-wide access.

For more information see the Plans and Pricing and Discount Schedule. Please contact us with any questions.

➤ See Plans and Pricing
Contact Sales

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Colorcon
Mallinckrodt
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.